NO333254B1 - Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom. - Google Patents

Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom.

Info

Publication number
NO333254B1
NO333254B1 NO20051426A NO20051426A NO333254B1 NO 333254 B1 NO333254 B1 NO 333254B1 NO 20051426 A NO20051426 A NO 20051426A NO 20051426 A NO20051426 A NO 20051426A NO 333254 B1 NO333254 B1 NO 333254B1
Authority
NO
Norway
Prior art keywords
clusterin
melanoma
composition
treatment
subject
Prior art date
Application number
NO20051426A
Other languages
English (en)
Other versions
NO20051426L (no
Inventor
Burkhard Jansen
Original Assignee
Gleave Martin
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gleave Martin, Univ British Columbia filed Critical Gleave Martin
Publication of NO20051426L publication Critical patent/NO20051426L/no
Publication of NO333254B1 publication Critical patent/NO333254B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Behandling av melanom oppnås ved reduksjon av den effektive mengden av clusterin i melanomceller. Ifølge et aspekt ved oppfinnelsen frembringer således en fremgangsmåte for å behandle et melanom hos et pattedyrindivid, fortrinnsvis et menneske, omfattende trinnene administrering til individet av et terapeutisk middel effektivt til å redusere den effektive mengden av clusterin i melanomcellene. Det terapeutiske middel kan for eksempel være et antisens-ODN eller lite inhibitorisk RNA (siRNA) forbindelse målrettet mot clusterin. Oppfinnelsen frembringer også en fremgangsmåte for å regulere ekspresjon av bcl-xL hos et individ eller en cellelinje omfattende administrering til individet eller cellelinjen av et middel effektivt til å modulere mengden av clusterinekspresjon. I særdeleshet, utløste clusterin uttrykkende celler nedreguleres ekspresjon av bcl-xL når den effektive mengden av clusterin reduseres. En slik inhibisjon er viktig fordi bcl-xL er kjent å virke som en inhibitor for apoptose.
NO20051426A 2002-08-21 2005-03-17 Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom. NO333254B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US31974802P 2002-12-02 2002-12-02
US47238703P 2003-05-20 2003-05-20
PCT/CA2003/001276 WO2004018675A1 (en) 2002-08-21 2003-08-21 Treatment of melanoma by reduction in clusterin levels

Publications (2)

Publication Number Publication Date
NO20051426L NO20051426L (no) 2005-05-12
NO333254B1 true NO333254B1 (no) 2013-04-22

Family

ID=31950766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051426A NO333254B1 (no) 2002-08-21 2005-03-17 Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom.

Country Status (16)

Country Link
US (1) US7285541B2 (no)
EP (1) EP1530636B1 (no)
JP (1) JP4620585B2 (no)
KR (1) KR101052289B1 (no)
AT (1) ATE478142T1 (no)
AU (1) AU2003258425B2 (no)
CA (1) CA2494764C (no)
CY (1) CY1110936T1 (no)
DE (1) DE60333839D1 (no)
DK (1) DK1530636T3 (no)
IL (1) IL166657A (no)
NO (1) NO333254B1 (no)
NZ (1) NZ538288A (no)
PT (1) PT1530636E (no)
SI (1) SI1530636T1 (no)
WO (1) WO2004018675A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534773B1 (en) 1999-02-26 2009-05-19 The University Of British Columbia TRPM-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004018676A2 (en) * 2002-08-21 2004-03-04 The University Of British Columbia Rnai probes targeting cancer-related proteins
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
EP1744788A4 (en) * 2004-03-19 2010-08-18 Penn State Res Found COMBINATIVE METHODS AND COMPOSITIONS FOR TREATING MELANOMA
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
JP4980919B2 (ja) * 2004-11-23 2012-07-18 ザ ユニバーシティー オブ ブリティッシュ コロンビア ユニバーシティー−インダストリー リエゾン オフィス Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
EP2368988A1 (en) * 2005-09-19 2011-09-28 Isis Pharmaceuticals, Inc. Modulation of Glucocorticoid Receptor Expression
AU2008293138A1 (en) * 2007-08-28 2009-03-05 Auckland Uniservices Limited Cell marker of melanocyte cell lineage and uses thereof
DK2504363T3 (da) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
JP2014509608A (ja) 2011-03-15 2014-04-21 ザ ユニバーシティ オブ ブリティッシュ コロンビア 前立腺癌を治療するための、抗クラステリンオリゴヌクレオチドとｈｓｐ９０阻害剤との併用
RU2014119787A (ru) 2011-10-25 2015-12-10 Айсис Фармасьютикалс, Инк. Антисмысловая регуляция экспрессии gccr
EP2817028A4 (en) 2012-02-22 2015-11-04 Alethia Biotherapeutics Inc COMMON USE OF A CLUSTERIN INHIBITOR AND EGFR INHIBITOR FOR TREATING CANCER
WO2014138338A1 (en) 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
US20140275215A1 (en) * 2013-03-14 2014-09-18 Teva Pharmaceutical Industries, Ltd. Anti-clusterin monotherapy for cancer treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
CA2323929C (en) * 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
AU3116800A (en) 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7534773B1 (en) * 1999-02-26 2009-05-19 The University Of British Columbia TRPM-2 antisense therapy
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
MXPA02006167A (es) 1999-12-21 2004-02-26 Univ Yale Promocion de la angiogenesis con survivina.
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004018676A2 (en) 2002-08-21 2004-03-04 The University Of British Columbia Rnai probes targeting cancer-related proteins
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8061408B2 (en) 2009-10-13 2011-11-22 Varel Europe S.A.S. Casting method for matrix drill bits and reamers

Also Published As

Publication number Publication date
US20040082534A1 (en) 2004-04-29
AU2003258425B2 (en) 2008-02-14
WO2004018675A1 (en) 2004-03-04
CA2494764C (en) 2013-04-23
IL166657A0 (en) 2006-01-15
KR101052289B1 (ko) 2011-07-27
CA2494764A1 (en) 2004-03-04
KR20050058425A (ko) 2005-06-16
IL166657A (en) 2010-05-31
US7285541B2 (en) 2007-10-23
CY1110936T1 (el) 2015-06-10
SI1530636T1 (sl) 2010-12-31
DK1530636T3 (da) 2010-11-29
PT1530636E (pt) 2010-11-17
NO20051426L (no) 2005-05-12
EP1530636B1 (en) 2010-08-18
EP1530636A1 (en) 2005-05-18
DE60333839D1 (de) 2010-09-30
JP2006502243A (ja) 2006-01-19
AU2003258425A1 (en) 2004-03-11
JP4620585B2 (ja) 2011-01-26
NZ538288A (en) 2008-04-30
ATE478142T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
NO333254B1 (no) Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom.
BRPI0410886A (pt) composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
WO2000049937A3 (en) Trpm-2 antisense therapy
Hwang et al. A mechanism of low molecular weight fucoidans degraded by enzymatic and acidic hydrolysis for the prevention of UVB damage
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2009001359A3 (en) Compositions and methods for inhibiting expression of pro-apoptotic genes
NZ598778A (en) Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
Yang et al. The role of CDR1as in proliferation and differentiation of human umbilical cord‐derived mesenchymal stem cells
NO20033665D0 (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BR0306643A (pt) Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
WO2006013193A8 (en) Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors
Li The role of MicroRNAs in vitiligo: Regulators and therapeutic targets
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
NZ616745A (en) Antisense formulation
KR102552776B1 (ko) miRNA를 포함하는 흑색종 전이 억제용 조성물
Park et al. Effects of xanthium stramarium and psoralea corylifolia extracts combined with UVA1 irradiation on the cell proliferation and TGF-β1 expression of keloid fibroblasts
AU2606000A (en) Antisense modulation of x-linked inhibitor of apoptosis expression
RU2015138544A (ru) Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран
WO2007121054A3 (en) Nucleic acids for apoptosis of cancer cells
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
WO2005040147A1 (ja) 抗腫瘍剤
BRPI0409980A (pt) uso de derivados de ácido fenoxiacético para tratar bexiga hiperativa
US20170175112A1 (en) Mir-21-3p inhibitors in skin disorders

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees